Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Nexavar

Bayer symbol

Bayer nets speedy US review for regorafenib in liver cancer

Priority review in HCC boosts hopes for rejuvenation of Stivarga to combat declining sales

- PMLiVE

Novartis’ former UK government affairs head launches consultancy

Oxygen Strategy will offer pharma clients a 'fresh approach to strategy'

Bayer symbol

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies

- PMLiVE

Novartis’ AMD drug pegpleranib fails phase III programme

Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit

- PMLiVE

Pfizer gets record £84m fine for hiking price of epilepsy drug

US firm plans to appeal after CMA finds it raised NHS fee by 2,600% in 2012

- PMLiVE

NICE U-turn sees Celgene’s Imnovid backed for multiple myeloma

New data and a discount swayed the cost-effectiveness body

Living with Crohn’s disease: a patient perspective

Account Executive Victoria Morton explores what it’s like to live with Crohn’s disease as a young person, and investigates what’s being done to tackle the gaps in treatment options for...

Blue Latitude Health

- PMLiVE

Bayer wins Company of the Year at PMEA 2016

Sees off strong competition from AbbVie, Celgene and Novartis

- PMLiVE

Hey You! campaign targets over 60s at high risk of stroke

Bayer launches atrial fibrillation awareness drive starring rock and roll

Bristol-Myers Squibb (BMS) building

NICE backs BMS leukaemia drug Sprycel

Watchdog approves blood cancer therapy for use by NHS in England and Wales

Roche's Perjeta pertuzumab

NICE backs Roche’s Perjeta for routine NHS use

Set to become first new breast cancer drug in nine years after discount agreed

- PMLiVE

The rise and rise of Generation Now

Investigating the positive changes millennials are bringing to healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links